Work

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Year: 2021

Type: article

Source: Cancer Cell

DOI: 10.1016/j.ccell.2021.11.002

Authors: Hongzhong Li, Yi Xiao, Qin Li, Jun Yao, Xiangliang Yuan, Yuan Zhang, Xuedong Yin, Yohei Saito, Huihui Fan, Ping Li, Wen-Ling Kuo, Angela Halpin, Don L. Gibbons, Hideo Yagita, Zhongming Zhao, Da Pang, Guosheng Ren, Cassian Yee, J. Jack Lee, Dihua Yu

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston, Juntendo University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, The Affiliated Yongchuan Hospital of Chongqing Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Cancer Prevention and Research Institute of Texas, METAvivor, National Institutes of Health, National Cancer Institute

Awards: G111615301, G3625791705, UTHealth Cancer Genomics Core (UTHealth CGC), G4618352136, G7841606727, G7912931432, Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC, G9000030360, G9000120086

OpenAlex ID: W3215077655

FWCI: 14.93

Cites: 62

Cited by: 287

Related to: 10